LD-2 disclosure · 2nd Quarter - Report
PFIZER INC.
via PFIZER INC.
Client
- Name
- PFIZER INC.
- Location
- District of Columbia · United States of America
Registrant
- Firm
- PFIZER INC.
- Description
- Biopharmaceuticals
- Location
- WASHINGTON, District of Columbia, United States of America
Lobbying activities
5 issuesCopyright/Patent/Trademark
IP Issues: Trade-Related Aspects of Intellectual Property Rights March-in Framework Guidance and Policies Digital: S2916 - Digital Communication of Prescribing Information for Drugs
LobbyistsEMILY MUELLER · CATHERINE ROBINSON · ELISSA ALBEN · STEPHEN CLAEYS · FRANCISCO CARRILLO
TargetedSENATE · HOUSE OF REPRESENTATIVES · U.S. Trade Representative (USTR) · Commerce, Dept of (DOC)
Health Issues
VICP Reform and Excise Tax, VICP Transition Inflation Reduction Act (IRA)/Medicare Price Setting HR7174 - Ensuring Pathways to Innovative Cures (EPIC) Act Medicare Price Setting Drug Shortages Antimicrobial Resistance (AMR) Policy S.2305 - Biosimilar Red Tape Elimination Act Biosimilar Access and Interchangeability IRA Mitigation H.R. 4925 - EPIC Act
LobbyistsPAULA BURG · EMILY MUELLER · CATHERINE ROBINSON · FRANCISCO CARRILLO · MATTHEW STROIA · ms JENNIFER SWENSON WALTON
TargetedSENATE · HOUSE OF REPRESENTATIVES
Medicare/Medicaid
PBM Transparency and Reform: S1375/HR830 - Help Ensure Lower Patient (HELP) Copays Act S1542/HR6283 - Delinking Revenue from Unfair Gouging (DRUG) Act S2973 - Modernizing and Ensuring PBM Accountability Act S3430 - Better Mental Health Care, Lower Cost Drugs, and Extenders Act HR2880 - Protecting Patients Against PBM Abuses Act HR5378 - Lower Costs More Transparency Act 340B Reform HR8574 - 340B Affording Care for Communities and Ensuring a Strong Safety-net Act HR8816 - American Medical Innovation and Investment Act of 2024